Article ID Journal Published Year Pages File Type
8537688 Pulmonary Pharmacology & Therapeutics 2018 37 Pages PDF
Abstract
The clinical study demonstrated that in subjects with poor inhalation technique the use of the AeroChamber Plus® Flow-Vu® spacer increased the bioavailability of Symbicort® pMDI to a level observed in subjects with good inhalation technique without a spacer. The findings from the in vitro study support the fine particle dose characteristics of Symbicort® pMDI with the AeroChamber Plus® Flow-Vu® spacer.
Related Topics
Health Sciences Medicine and Dentistry Pulmonary and Respiratory Medicine
Authors
, , , , , , , ,